1-855-378-42281-855-378-4228
One of the out-patient rehabilitation alternatives for clients in Kearny struggling with opioid dependence and addiction is called opioid maintenance therapy. Some centers and doctors are certified to dispense certain medications to opioid dependent clients, many of which are opioids also and are addiction. With low enough doses however, the individual does not experience being high but also doesn't have intense cravings and isn't experiencing opioid withdrawal. Methadone is the first med tried for this reason, but there are alternative options to select from.
Methadone is an opioid and is meant to be taken at an outpatient medical center certified to administer the drug, that is taken on a daily basis as a pill or liquid. The cost of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opiate based med, and is a pill often taken one day on, one day off. But different from Methadone that can only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is about $300.00 monthly for the generic version of the med. There is also a version of buprenorphine that contains the ingredient naloxone, that is a drug which reverses the effects of opioids. An individual taking this formulation, AKA Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and costs approximately $450 a month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other drugs aforementioned it's an opioid blocker and isn't an opioid. There is an option to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 a month.
For All Drug and Alcohol Treatment Programs In Kearny, Click Here.
